Assay News and Research

RSS

COVID boosters hinder SARS-CoV-2 Omicron

A new preprint research paper reports on the state of current knowledge as to the immune evasion capability of this variant, linking it to the type of vaccine used and the vaccination protocol.

6 Jan 2022

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose.

5 Jan 2022

New CRISPR-based assay can non-invasively detect a biomarker of acute kidney rejection in urine

When a patient receives a kidney transplant, doctors carefully monitor them for signs of rejection in several ways, including biopsy. However, this procedure is invasive and can only detect issues at a late stage.

5 Jan 2022

Exploring SARS-CoV-2-like viruses to mitigate the risk of zoonotic transmission to humans

In a new study, a team of researchers developed a genetic assay to evaluate several clade 2 and clade 3 receptor-binding domains (RBD) of spike (S) protein sequences of genus sarbecovirus.

5 Jan 2022

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

COVID-19 mRNA vaccines offer protection against Omicron variant in pregnancy

A new study provides insights into the persistence of extra-neutralizing properties of mRNA vaccine-induced antibodies resulting in protection against the Omicron variant of SARS-CoV-2.

5 Jan 2022

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

Results from a new study could be crucial in studying the molecular and biochemical basis of SARS-CoV-2 infection at a more granular level and help in strategizing therapeutic solutions to treat and manage COVID-19 effectively.

5 Jan 2022

Can the COVID-19 delta variant evade vaccine-induced immunity?

Can the COVID-19 delta variant evade vaccine-induced immunity? We spoke to Professor Brian J. Willett from the University of Glasgow to find out.

5 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Time since COVID vaccination is a key driver of breakthrough Omicron infections

Published on the preprint medRxiv* server and awaiting peer review, the findings showed that the significant factor behind breakthrough Omicron infections is the timing from vaccination. The time between vaccination and breakthrough infections induced effective or cross-reactive neutralizing antibodies that neutralize Omicron after Alpha or Delta breakthrough infections.

4 Jan 2022

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.

From Sino Biological Inc. 4 Jan 2022

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

COVID-19 tests with the new assay may be just as reliable as laboratory-based molecular tests

Researchers at the University of Illinois Chicago have designed a high-quality assay that can be used in at-home tests for rapid COVID-19 screening.

3 Jan 2022

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Researchers investigate the ability of immunity acquired from SARS-CoV-2 wild-type infection to protect against the Omicron variant in Syrian hamster models.

3 Jan 2022

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

Researchers investigate the neutralizing antibody activity against different variants of SARS-CoV-2 in fully immunized elderly individuals.

3 Jan 2022

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Researchers investigated the potency of trimeric human nephrocystin SH3, TriSb92, a domain-derived antibody, against a conserved region in the receptor-binding domain (RBD) of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

31 Dec 2021

Altered cytokine profiles of COVID-19-infected mother-infant dyads may impair long-term infant health

New study findings suggest that both SARS-CoV-2-infected mothers and their fetuses have increased levels of inflammatory cytokines throughout gestation, which may potentially impact fetus health in the long term.

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Researchers carried out an analytical susceptibility test with cultured SARS-CoV-2 Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs).

29 Dec 2021

Assay News and Research

COVID boosters hinder SARS-CoV-2 Omicron

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

New CRISPR-based assay can non-invasively detect a biomarker of acute kidney rejection in urine

Exploring SARS-CoV-2-like viruses to mitigate the risk of zoonotic transmission to humans

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

COVID-19 mRNA vaccines offer protection against Omicron variant in pregnancy

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

Can the COVID-19 delta variant evade vaccine-induced immunity?

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

Time since COVID vaccination is a key driver of breakthrough Omicron infections

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

COVID-19 tests with the new assay may be just as reliable as laboratory-based molecular tests

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Altered cytokine profiles of COVID-19-infected mother-infant dyads may impair long-term infant health

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News